[DRRX] DURECT Corporation

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 195.05 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.28 Change: 0.04 (3.23%)
Ext. hours: Change: 0 (0%)

chart DRRX

Refresh chart

Strongest Trends Summary For DRRX

DRRX is in the medium-term up 254% in 1 year and up 281% in 2 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: DURECT Corporation, a specialty pharmaceutical company, is engaged in the development of pharmaceutical products based on its proprietary drug delivery technology platforms in the United States and internationally. It focuses on the development of various products for the treatment of various chronic and episodic disease areas, such as pain, central nervous system disorders, metabolic disorders, cardiovascular disease, and other chronic diseases. The company?s products comprise ALZET product line that consists of osmotic pumps and accessories, which are used for experimental research in mice, rats, and other laboratory animals; and a range of standard and custom biodegradable polymers that are used as raw materials in the pharmaceutical and medical devices under the brand name of LACTEL. Its products also include REMOXY, an oral oxycodone gelatin capsule for chronic pain; POSIDUR, a formulation of bupivacaine for the treatment of post-surgical pain that has completed Phase III clinical study; ELADUR, a Phase

Fundamental Ratios
Shares Outstanding137.36 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 4.19% Sales Growth - Q/Q11.81% P/E
P/E To EPS Growth P/S10.91 P/BV12.6 Price/Cash Per Share6.72
Price/Free Cash Flow-13.53 ROA-51.33% ROE-150.97% ROI-65.53%
Current Ratio5.02 Quick Ratio4.5 Long Term Debt/Equity0.62 Debt Ratio0.47
Gross Margin68.52% Operating Margin-122.01% Net Profit Margin-130.66% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities240 K Cash From Investing Activities4.42 M Cash From Operating Activities-5.35 M Gross Profit3.77 M
Net Profit-4.85 M Operating Profit-4.42 M Total Assets45.52 M Total Current Assets36.47 M
Total Current Liabilities7.26 M Total Debt19.84 M Total Liabilities30.04 M Total Revenue4.77 M
Technical Data
High 52 week2.21 Low 52 week0.48 Last close1.85 Last change2.78%
RSI36.19 Average true range0.16 Beta1.38 Volume369.5 K
Simple moving average 20 days-3.34% Simple moving average 50 days8.43% Simple moving average 200 days97.62%
Performance Data
Performance Week1.65% Performance Month5.71% Performance Quart164.29% Performance Half207.87%
Performance Year90.72% Performance Year-to-date282.94% Volatility daily5.23% Volatility weekly11.7%
Volatility monthly23.99% Volatility yearly83.09% Relative Volume282.28% Average Volume1.19 M
New High New Low

News

2020-05-28 09:00:00 | DURECT to Present at the Jefferies 2020 Virtual Health Care Conference

2020-05-26 08:30:00 | DURECT Corporation Announces Positive Topline Data from Phase 1b Study of DUR-928 in NASH

2020-05-20 10:04:41 | Billionaire Jim Simons Pulls the Trigger on These 3 Healthcare Stocks

2020-05-12 15:00:37 | Durect Corp DRRX Q1 2020 Earnings Call Transcript

2020-05-12 14:20:00 | Here's Why Shares of Durect Jumped Higher Today

2020-05-11 18:55:10 | Durect DRRX Reports Q1 Loss, Misses Revenue Estimates

2020-05-11 16:05:00 | DURECT Corporation Announces First Quarter 2020 Financial Results and Update of Programs

2020-05-04 17:00:00 | DURECT Corporation to Announce First Quarter 2020 Financial Results and Provide Business Update on May 11

2020-04-28 12:33:04 | Durect DRRX May Report Negative Earnings: Know the Trend Ahead of Q1 Release

2020-03-06 21:24:49 | Edited Transcript of DRRX earnings conference call or presentation 3-Mar-20 9:30pm GMT

2020-03-04 07:37:10 | The Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics Companies

2020-03-03 16:05:00 | DURECT Corporation Announces Fourth Quarter and Full Year 2019 Financial Results and Update of Programs

2020-02-26 07:30:00 | DURECT Corporation to Announce 2019 Financial Results on March 3

2020-02-10 08:05:31 | 3 “Strong Buy” Healthcare Stocks With Triple-Digit Upside

2020-01-31 11:14:18 | 5 Stocks Under $5 With Colossal Growth Prospects

2020-01-17 08:19:00 | UPDATE: Durect stock slides after FDA committee ends meeting with split vote on post-surgical pain treatment

2020-01-17 08:07:09 | The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares

2020-01-17 06:45:00 | DURECT Corporation Announces Outcome of FDA Advisory Committee Meeting for POSIMIR®

2020-01-16 14:38:46 | U.S. FDA panel split over approval of Durect's non-opioid painkiller

2020-01-16 07:24:00 | Biopharma Durect shares halted ahead of FDA committee meeting on post-surgical pain treatment

2020-01-16 07:05:00 | DURECT Corporation Trading Halted Today; FDA Advisory Committee to Discuss POSIMIR® bupivacaine extended-release solution for Post-Surgical Analgesia

2020-01-13 13:31:13 | Top Pharmaceutical Stocks for Q1 2020

2020-01-02 17:28:30 | Drug developer dips on failed psoriasis trial

2020-01-02 10:08:00 | Durect's stock tumbles after failed psoriasis trial

2020-01-02 09:00:00 | DURECT Corporation Announces Top-Line Results from Phase 2a Clinical Trial in Patients with Psoriasis

2019-12-30 09:24:15 | 3 Healthcare Stocks With Huge FDA Decisions in January

2019-12-29 18:38:06 | Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus

2019-12-19 17:02:00 | Hedge Funds Had Impeccable Timing Buying DURECT Corporation DRRX

2019-11-15 08:00:00 | DURECT to Present at the Stifel 2019 Health Care Conference

2019-11-12 08:45:00 | DURECT Corporation Announces Positive Results from the Phase 2a Clinical Trial of DUR-928 in Alcoholic Hepatitis Patients in a Late-Breaking Presentation at The Liver Meeting®

2019-11-08 15:27:23 | Edited Transcript of DRRX earnings conference call or presentation 4-Nov-19 9:30pm GMT

2019-11-06 17:47:00 | DURECT to Host Key Opinion Leader Call on DUR-928 Phase 2a Alcoholic Hepatitis Study Results

2019-11-04 16:05:00 | DURECT Corporation Announces Third Quarter 2019 Financial Results and Update of Programs

2019-10-30 08:00:00 | DURECT Corporation to Announce Third Quarter 2019 Financial Results and Provide Business Update on November 4

2019-10-21 10:12:00 | DURECT Announces DUR-928 Phase 2a Alcoholic Hepatitis Study Results Selected for Late-Breaking Oral Presentation at The Liver Meeting® 2019

2019-10-18 10:23:24 | These 24 Bay Area drug and diagnostics companies quietly raised nearly $3B this year

2019-10-17 16:05:00 | DURECT to Present at Two Upcoming NASH Investor Conferences

2019-10-07 08:00:00 | DURECT Announces Completion of Enrollment in its Phase 2a Clinical Trial of DUR-928 in Psoriasis and 50% Enrollment in its Phase 1b DUR-928 Clinical Trial in NASH

2019-10-02 08:00:00 | DURECT Announces FDA Advisory Committee Meeting to Review POSIMIR® for the Treatment of Post-Surgical Pain

2019-09-26 08:00:00 | DURECT to Present at the 2019 Cantor Fitzgerald Global Health Care Conference

2019-09-18 07:39:49 | The Daily Biotech Pulse: NewLink Genetics Rallies, Breakthrough Designation For Roche, IGM Biosciences Debuts

2019-09-17 08:00:00 | DURECT Announces Positive Data from its Phase 2a Clinical Trial of DUR-928 in Alcoholic Hepatitis

2019-09-09 09:29:00 | DURECT Earns $10 Million Milestone Payment for Further Development of a Long-Acting Injectable HIV Investigational Product Utilizing DURECT's SABER® Technology

2019-09-07 12:19:00 | 3 Biotech Stocks That Could Double Your Money

2019-09-06 12:24:00 | Why Durect Stock Is Up Today

2019-09-04 08:00:00 | DURECT to Present at the 21st Annual Rodman and Renshaw Global Investment Conference Sponsored by H.C. Wainwright

2019-08-20 10:00:00 | DRRX: Gilead Agreement, Near-Term Value-Inflection Opportunities Make DRRX Particularly Attractive at Current Valuation

2019-08-02 09:47:12 | Edited Transcript of DRRX earnings conference call or presentation 1-Aug-19 8:30pm GMT

2019-08-01 16:05:00 | DURECT Corporation Announces Second Quarter 2019 Financial Results and Update of Programs

2019-07-29 10:08:38 | Health Care Digest: Kilroy's Oyster Point mystery, helping researchers ditch spreadsheets — and more